Market Place
Sourcing Support
Layoffs, end of line for Synlogic after PKU drug`s phase 3 fail
09 Feb 2024 //
FIERCE BIOTECH
Synlogic Partners with Science 37 on Study for Investigational Drug for PKU
11 Jul 2023 //
GLOBENEWSWIRE
Synlogic’s SYNB1934 receives orphan drug status from US FDA
10 May 2023 //
PHARMACEUTICAL TECHNOLOGY
SQZ, Synlogic pulled into biotech’s layoff sinkhole
01 Dec 2022 //
FIERCEBIOTECH
Synlogic preps phenylketonuria drug for phase 3 after mid-stage win
19 Oct 2022 //
PHARMAPHORUM
Synlogic receives US FDA fast track designation for SYNB1353
24 Aug 2022 //
PHARMABIZ
Synlogic Announces Synthetic Biotic for Gout Developed inPartnership with Ginkgo
11 Aug 2022 //
PRESS RELEASE
Synlogic Announces Presentation of Phenylketonuria Data 14th Congress
10 Nov 2021 //
PRNEWSWIRE
Synlogic and Ginkgo Bioworks Announce Investigational Synthetic Biotic Medicine
09 Nov 2021 //
PRESS RELEASE
Synlogic Announces Nature Publication Demonstrating Novel Application
12 Oct 2021 //
PRNEWSWIRE
Synlogic Announces Proposed Public Offering of Common Stock
22 Sep 2021 //
PRNEWSWIRE
Synlogic Announces Positive Phase 2 Data for SYNB1618
20 Sep 2021 //
PRNEWSWIRE
Synlogic Announces Second Quarter 2021 Conference Call
05 Aug 2021 //
PRNEWSWIRE
Synlogic Announces Second Quarter 2021 Conference Call & Participation
05 Aug 2021 //
PRNEWSWIRE
Synlogic Announces Initiation of Phase 1 Study of SYNB1934
15 Jul 2021 //
PR NEWSWIRE
Synlogic Presents Data Activity of a Solid Oral Formulation of SYNB1618
13 Apr 2021 //
PRNEWSWIRE
Synlogic Presents Data from SYNB1891 Phase 1 Trial at (AACR) Annual Meeting
09 Apr 2021 //
PRNEWSWIRE
Synlogic Announces SYNB8802 Will Advance to Phase 1B Proof of Concept Study
24 Mar 2021 //
PRNEWSWIRE
Synlogic Announces SYNB8802 Will Advance to Phase 1B Proof of Concept
24 Mar 2021 //
PRNEWSWIRE
Synlogic Announces Promotion of Dr. Caroline Kurtz to Chief Development Officer
08 Mar 2021 //
PRNEWSWIRE
Synlogic Outlines Upcoming Clinical Milestones
11 Jan 2021 //
PRESS RELEASE
Synlogic Announces Advancement of SYNB1891 to Combination Arm Dosing
14 Dec 2020 //
PRESS RELEASE
Synlogic Announces Advancement of SYNB1891 to Combination Arm Dosing with PD-L1
14 Dec 2020 //
PRNEWSWIRE
Synlogic Presents SYNB8802 for Enteric Hyperoxaluria at the American Institute
07 Dec 2020 //
PRNEWSWIRE
Synlogic Presents SYNB8802 for Enteric Hyperoxaluria at the American Institute
07 Dec 2020 //
PRESS RELEASE
Synlogic begins SYNB8802 study for enteric hyperoxaluria treatment
05 Nov 2020 //
CLINICALTRIALSARENA
Synlogic Initiates Phase 1 Study of SYNB8802 for the Treatment
04 Nov 2020 //
PRNEWSWIRE
Synlogic Presents Preclinical Data on SYNB8802 for Enteric Hyperoxaluria
22 Oct 2020 //
PRNEWSWIRE
Synlogic Announces Termination of AbbVie Collaboration Agreement
21 May 2020 //
PR NEWSWIRE
Synlogic Provides Summary of Impact of COVID-19 on Clinical Program
30 Mar 2020 //
PRNEWSWIRE
Synlogic CEO Brennan on lessons learned and what`s up in 2020
14 Jan 2020 //
FIERCE BIOTECH
